[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69724241D1 - Gdnf-rezeptor und dessen verwendung - Google Patents

Gdnf-rezeptor und dessen verwendung

Info

Publication number
DE69724241D1
DE69724241D1 DE69724241T DE69724241T DE69724241D1 DE 69724241 D1 DE69724241 D1 DE 69724241D1 DE 69724241 T DE69724241 T DE 69724241T DE 69724241 T DE69724241 T DE 69724241T DE 69724241 D1 DE69724241 D1 DE 69724241D1
Authority
DE
Germany
Prior art keywords
gdnfrα
gdnf
methods
antibodies
gdnf receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69724241T
Other languages
English (en)
Other versions
DE69724241T2 (de
Inventor
D Klein
W Moore
Arnon Rosenthal
M Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69724241D1 publication Critical patent/DE69724241D1/de
Publication of DE69724241T2 publication Critical patent/DE69724241T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69724241T 1996-03-14 1997-03-13 Gdnf-rezeptor und dessen verwendung Expired - Lifetime DE69724241T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61590296A 1996-03-14 1996-03-14
US61823696A 1996-03-14 1996-03-14
US615902 1996-03-14
US618236 1996-03-14
PCT/US1997/004363 WO1997033912A2 (en) 1996-03-14 1997-03-13 Uses of gdnf and gdnf receptor

Publications (2)

Publication Number Publication Date
DE69724241D1 true DE69724241D1 (de) 2003-09-25
DE69724241T2 DE69724241T2 (de) 2004-06-09

Family

ID=27087630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724241T Expired - Lifetime DE69724241T2 (de) 1996-03-14 1997-03-13 Gdnf-rezeptor und dessen verwendung

Country Status (12)

Country Link
US (4) US6504007B1 (de)
EP (1) EP0888385B1 (de)
JP (1) JP4301347B2 (de)
AT (1) ATE247667T1 (de)
AU (1) AU719482B2 (de)
CA (1) CA2246768C (de)
DE (1) DE69724241T2 (de)
DK (1) DK0888385T3 (de)
ES (1) ES2206695T3 (de)
IL (1) IL125839A0 (de)
PT (1) PT888385E (de)
WO (1) WO1997033912A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
ES2206695T3 (es) 1996-03-14 2004-05-16 Genentech, Inc. Receptor de gdnf y utiolizacion del mismo.
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
KR100587556B1 (ko) * 1996-05-08 2006-06-08 바이오겐 아이덱 엠에이 인코포레이티드 신경 및 신장 증식을 자극하기 위한 ＲＥＴ리간드（ＲｅｔＬ)
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU765070B2 (en) * 1998-03-23 2003-09-11 Genentech Inc. GFRalpha3 and its uses
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
GB9915200D0 (en) 1999-06-29 1999-09-01 Janssen Pharmaceutica Nv Neurotrophic factor receptor
EP2272533A1 (de) * 2003-01-13 2011-01-12 MacroGenics, Inc. Lösliche FcyR-Fusionsproteine und Verfahren zu deren Verwendung
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
EP1863530B1 (de) * 2005-03-11 2010-07-14 Oncotherapy Science, Inc. Verfahren zur schädigung von zellen mit effektorfunktionen von anti-gfra1-antikörpern
CN103301475B (zh) 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
KR101829469B1 (ko) 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
ES2637063T3 (es) 2008-12-04 2017-10-10 Curna, Inc. Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
CN102341498B (zh) * 2008-12-04 2017-12-19 库尔纳公司 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
JP6066035B2 (ja) * 2009-02-12 2017-01-25 クルナ・インコーポレーテッド グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
EP2396038B1 (de) 2009-02-12 2015-10-21 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
CN102803492B (zh) 2009-05-06 2016-06-29 库尔纳公司 通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2432881B1 (de) 2009-05-18 2017-11-15 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
EP2432882B1 (de) 2009-05-22 2019-12-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
JP5960049B2 (ja) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
CN102612560B (zh) 2009-06-16 2017-10-17 库尔纳公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
US8921330B2 (en) 2009-06-26 2014-12-30 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
ES2585360T3 (es) 2009-08-05 2016-10-05 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
EP2467482A4 (de) 2009-08-21 2013-12-11 Curna Inc Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
WO2011038210A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
NO2513310T3 (de) 2009-12-16 2018-03-31
EP2516648B1 (de) 2009-12-23 2017-11-08 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem häpatozyten-wachstumsfaktor (hgf) mittels hemmung des natürlichen antisense-transkripts gegen hgf
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
CN102782134B (zh) 2009-12-29 2017-11-24 库尔纳公司 通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
EP2519634B1 (de) 2009-12-29 2016-06-01 CuRNA, Inc. Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
WO2011082281A2 (en) 2009-12-31 2011-07-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
ES2664605T3 (es) 2010-01-04 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
EP2524039B1 (de) 2010-01-11 2017-11-29 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem sexualhormonbindenden globulin (shgb) mittels hemmung des natürlichen antisense-transkripts gegen shbg
RU2611192C2 (ru) 2010-01-25 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
EP2539452B1 (de) 2010-02-22 2016-07-27 CuRNA, Inc. Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
CN102869777B (zh) 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
CN102933711B (zh) 2010-05-03 2018-01-02 库尔纳公司 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
KR101902197B1 (ko) 2010-05-26 2018-10-01 큐알엔에이, 인크. 메티오닌 설폭시드 환원효소 a (msra)에 대한 자연 안티센스 전사체의 저해에 의한 메티오닌 설폭시드 환원효소 a (msra) 관련된 질환의 치료
KR102152931B1 (ko) 2010-06-23 2020-09-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
WO2012009402A2 (en) 2010-07-14 2012-01-19 Opko Curna Llc Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
JP6049623B2 (ja) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
CA2818824A1 (en) 2010-11-23 2012-05-31 Joseph Collard Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US10583128B2 (en) 2011-09-06 2020-03-10 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
PT2825648T (pt) 2012-03-15 2018-11-09 Scripps Research Inst Tratamento de doenças relacionadas ao fator neurotrófico derivado do cerebro (bdnf) por inibição da transcrição anti-sentido natural ao bdnf
EP3436078B1 (de) * 2016-03-31 2021-10-27 University of Cincinnati Verfahren und zusammensetzungen zur behandlung von als
WO2022046771A1 (en) * 2020-08-24 2022-03-03 The Johns Hopkins University Juvenile protective factors to arrest and reverse aging in the enteric nervous system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
AU6709794A (en) 1993-04-21 1994-11-08 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
WO1995013376A1 (en) 1993-11-10 1995-05-18 Amgen Inc. Gene therapy vector for the treatment of low or defective red blood cell production
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
ES2206695T3 (es) 1996-03-14 2004-05-16 Genentech, Inc. Receptor de gdnf y utiolizacion del mismo.
WO1997039912A2 (de) 1996-04-18 1997-10-30 Siemens Aktiengesellschaft Stromversorgungssystem für einen langstatorantrieb
US6635668B1 (en) 1998-07-22 2003-10-21 The University Of North Carolina At Chapel Hill Imidazoline receptor binding compounds
PT1813624E (pt) 1998-10-23 2010-10-27 Amgen Inc Métodos e composições para a prevenção e tratamento da anemia

Also Published As

Publication number Publication date
DE69724241T2 (de) 2004-06-09
JP2000511402A (ja) 2000-09-05
JP4301347B2 (ja) 2009-07-22
US20100313283A1 (en) 2010-12-09
US20030022284A1 (en) 2003-01-30
CA2246768A1 (en) 1997-09-18
US7691606B2 (en) 2010-04-06
AU2217297A (en) 1997-10-01
US6504007B1 (en) 2003-01-07
ATE247667T1 (de) 2003-09-15
US7105484B2 (en) 2006-09-12
IL125839A0 (en) 1999-04-11
CA2246768C (en) 2013-12-31
ES2206695T3 (es) 2004-05-16
EP0888385A2 (de) 1999-01-07
US20060142196A1 (en) 2006-06-29
WO1997033912A3 (en) 1998-02-05
AU719482B2 (en) 2000-05-11
EP0888385B1 (de) 2003-08-20
DK0888385T3 (da) 2003-12-15
PT888385E (pt) 2004-01-30
WO1997033912A2 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
DE69724241D1 (de) Gdnf-rezeptor und dessen verwendung
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
NO20003550L (no) Farmasøytiske sammensetninger og anvendelse herav
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
IL215027A (en) Anti-zb7r1 antibody, a formula containing it, and a method of increasing lymphocyte activity with its help
EA200200647A1 (ru) АГОНИСТЫ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
WO1999000410A3 (en) Human extracellular matrix proteins
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
YU83600A (sh) Adenozin a3 receptorski modulatori
WO2007070671A3 (en) Therapeutic methods for inhibiting tumor growth with dll4 antagonists
DK0584082T3 (da) Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE69832797D1 (de) Neurturin-rezeptor
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
TR199700956T1 (xx) Indazolkarboksamidler.
PT1283217E (pt) Anticorpos contra o receptor de il-8, e suas utilizações terapêuticas
AU9363398A (en) Hepatitis c receptor protein cd81
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.
DE69633131D1 (de) Rezeptor des y-y5 neuropeptids
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
Meng Involvement of the striatum and the striatial adenosine in acute ethanol-induced motor impairment in rats.
DE602004027387D1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren
WO2000042172A3 (en) Human homologues of proteins regulated by circadian rhythms

Legal Events

Date Code Title Description
8364 No opposition during term of opposition